CompletedNot Applicable

Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy

Spain94 participantsStarted 2019-01-10

Plain-language summary

Cross-sectional study. We will prospectively obtain ddcf-DNA levels in all patients who undergo routine coronary angiography \> 1 year after HT. Our main goal is to evaluate the performance of Donor-derived Cell Free DNA (ddcf-DNA) as a biomarker of CAV.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients over 18 and under 80 years old, HT \> 1 year ago Exclusion Criteria: * Patients under 18 or over 80 years old * Multiorgan transplant * History of acute cellular rejection ≥ 1R or antibody mediated rejection in the previous 6 months * Concomitant infection by CMV

What they're measuring

Correlation between ddcf-DNA and CAV

Timeframe: 2 years

Performance of the biomarker for the diagnosis of CAV

Timeframe: 2 years

Trial details

NCT IDNCT04791852

SponsorPuerta de Hierro University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-01-31

View on ClinicalTrials.gov More Cardiac Allograft Vasculopathy trials